



INDO US
BIO-TECH LIMITED
(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Date: 12th August, 2023

To,
General Manager,
Corporate Relationship,
BSE Limited, P J Tower,
Dalal Street,
Mumbai — 400 001

**Sub: Outcome of Board Meeting held on August 12, 2023, pursuant to Regulation 30 of the SEBI
(Listing Obligation and Disclosure Requirements) Regulations, 2015.**

Scrip Code: 541304

Ref: Indo Us Bio Tech Limited

Dear Sir,

Pursuant to the Regulation 30 of the SEBI (Listing Obligation and Disclosures Requirements) Regulation, 2015, we wish to inform you that the Board of Directors of the Company at their meeting held on Saturday, 12th August 2023 at the registered office of the Company situated at 309, Shanti Mall, Satadhar Char Rasta, Opp. Navrang Tower, Sola Road, Ahmedabad, Gujarat, 380061 have considered and approved the following items of business:

1. The Board approved unaudited financial results of the company for the quarter ended 30th June, 2023 along with limited review reports obtained from the Auditor of the Company.

The Board Meeting commenced at 05.30 P.M. and concluded at 06:30 P.M.

You are requested to kindly take the same on record.

Thanking you,

For, Indo us Bio Tech Limited

DIMPY
DIVYANGBHAI
JOSHI
Date: 2023.08.12
18:50:22 +05'30'

Digitally signed by
DIMPY DIVYANGBHAI
JOSHI

Ms. Dimpy Joshi
Company Secretary & Compliance officer



Regd. Office :
309, Shanti Mall, Satadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999

DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanthi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indous_jagdish@yahoo.co.in • indo-us_agrisciences@hotmail.com
Web : www.indousagriseeds.com



INDO US

BIO-TECH LIMITED

(AN ISO CERTIFIED COMPANY)
CIN LO1122GJ2004PLC043550



Indo US Bio-Tech Limited

Statement of standalone Unaudited financial results for the quarter ended on 30th June 2023

PARTICULARS	Quarter Ended			3 Months ended		(Amount in Lakhs)
	30-06-2023 (Unaudited)	31-03-2023 (Audited)	30-06-2022 (Unaudited)	30-06-2023 (Unaudited)	30-06-2022 (Unaudited)	Year ended 31-03-2023 (Audited)
I Income						
Revenue from operations	1,914.26	1,811.05	1,438.31	1,914.26	1,438.31	6,174.48
Other income	2.86	1.74	0.04	2.86	0.04	2.08
Total income from operations	1,917.12	1,812.78	1,438.35	1,917.12	1,438.35	6,176.56
II Expenses						
Purchases	107.61	188.99	250.70	107.61	250.70	526.79
Production Expenses	775.10	1,823.60	702.84	775.10	702.84	4,297.17
Change in Inventories	550.67	(697.12)	106.90	550.67	106.90	(312.39)
Employee benefit expenses	31.74	44.43	34.35	31.74	34.35	152.50
Finance costs	37.21	28.30	28.46	37.21	28.46	118.43
Depreciation and amortization expenses	20.05	25.65	16.15	20.05	16.15	82.59
Other expenses	149.99	185.24	119.11	149.99	119.11	572.78
Total expenses	1,672.39	1,599.10	1,258.51	1,672.39	1,258.51	5,437.87
III Profit/(Loss) before exceptional items and tax	244.73	213.69	179.83	244.73	179.83	738.68
IV Exceptional items- Prior Period Items						
V Profit/(Loss) before tax						
VI Tax expenses						
a) Current tax	11.62	8.48	-	11.62	-	33.93
b) Income tax prior year	-	(0.60)	-	-	-	(2.41)
c) Deferred tax	(4.22)	(4.22)	-	(4.22)	-	(16.88)
Total tax expenses	7.41	3.66	-	7.41	-	14.65
VII Net Profit/(Loss) for the period/year	237.32	210.03	179.83	237.32	179.83	724.04
VIII Other comprehensive income (net of tax)						
Items that will not be reclassified to profit or loss:						
a) Remeasurement of post employment benefit obligations	-	-	-	-	-	-
b) Income-tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
Total other comprehensive income	-	-	-	-	-	-
IX Total comprehensive income for the period/year (VII+VIII)	237.32	210.03	179.83	237.32	179.83	724.04
X Paid-up equity share capital (face value of Rs. 10 per share)	1,002.60	1,002.60	916.67	1,002.60	916.67	1,002.60
XI Other equity (excluding revaluation reserve)	4,684.30	4,446.98	3,151.07	4,684.30	3,151.07	4,446.98
XII EPS in Rs. (Face Value of Rs.10/- each)*						
-Basic	2.37	2.09	1.96	2.37	1.96	7.51
-Diluted	2.37	2.09	1.96	2.37	1.96	7.51
*not annualised						

Notes

(1) The financial results were reviewed by the Audit Committee and approved by the Board of Directors of its meeting held on 12th August 2023 and the Statutory Auditors of the Company have expressed an unmodified opinion on these results.

(2) The company is dealing in one major product segment, i.e. Seed Cultivation, Processing & Trading.

(3) There were no investor complaints pending /received during the period under review.

(4) The figures have been grouped under heads wherever applicable.

Place: Ahmedabad
Date: 12-08-2023




GAUTAM N ASSOCIATES
CHARTERED ACCOUNTANTS

(PARTNER)

UDIN: 23032742B6F5003369

Regd. Office:
309, Shanti Mall, Sattadhar Cross Road,
Opp. Navrang Tower, Ahmedabad-380 061.
Tele Fax : +91-079-27491807,
Mobile : +91-9909043999



For and on behalf of Board of Directors

Madan D. Ajudiya
Managing Director
CIN: 01745951

DSIR RECOGNITION IN HOUSE R&D UNIT
Factory Address :
Village-Bardoli Kanhi,
Near Indira Nagar, Ta.-Dehgam,
Dist-Gandhinagar, Gujarat.

E-mail : indousextm@gmail.com • Web : www.indousagri.com



Gautam N Associates

Chartered Accountants

30, GNA House, Behind ABC Complex,
Manmandir Travels Lane, Adalat Road, Aurangabad - 431 001

INDEPENDENT AUDITOR'S REVIEW REPORT ON THE QUARTERLY AND YEAR TO DATE UNAUDITED STANDALONE IND-AS FINANCIAL RESULTS OF THE COMPANY PURSUANT TO REGULATION 33 OF SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATION 2015, AS AMENDED.

Review Report to
The Board of Directors,
Indo US Bio-tech Limited

1. We have reviewed the accompanying statement of unaudited Standalone Ind-AS financial results of Indo US Bio-tech Limited (CIN: L01122GJ2004PLC043550) ('the Company') for the quarter ended 30th June 2023 and year to date results for the period 1st April 2023 to 30th June 2023 ('The Statement') being submitted by the Company pursuant to the requirements of regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulation 2015 as amended.
2. This statement, which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with Ind-AS 34- 'Interim Financial Reporting' prescribed under section 133 of the Companies Act., 2013 read with relevant rules issued thereunder and other recognised accounting practices and policies generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Gautam N Associates
Chartered Accountants
FRN: 103117W



Gautam Nandawat
Partner

M No: 032742

UDIN: **23032742BGSSOO3364**



Place: Aurangabad
Date: 12th August 2023